RxSight Reports Q2 2026 Revenue of $33.7 Million, Faces Decline in Product Sales

RxSight, Inc. reported its financial results for the second quarter of 2026, revealing a total revenue of $33.7 million, a slight increase of 0.3% compared to $33.6 million in the same period last year. The revenue breakdown showed a significant decline in product sales, which fell by 19% to $27.2 million from $33.6 million, primarily due to decreased unit sales of both Light Delivery Devices (LDDs) and Light Adjustable Lenses (LALs). However, the company recorded $6.5 million in collaboration revenue from its recent agreement with Alcon Pharmaceuticals, marking a new revenue stream that was not present in the previous year.

In terms of expenses, total costs remained relatively stable at $47.5 million, a slight decrease of 0.3% from $47.6 million in the prior year. Cost of sales decreased by 7% to $7.9 million, reflecting the lower volume of products sold. Selling, general, and administrative expenses increased by 5% to $30.4 million, driven by higher professional services fees, while research and development expenses decreased by 9.6% to $9.2 million due to reduced headcount and project completions. The net loss for the quarter was $12.1 million, slightly higher than the $11.8 million loss reported in the same quarter of 2025.

Operationally, RxSight has established a global installed base of 1,166 LDDs as of June 30, 2026, with approximately 357,000 LALs implanted since the company's inception. The company aims to expand its sales organization and increase the number of trained doctors to drive product adoption. RxSight's leadership transition, with Aziz Mottiwala appointed as CEO, is expected to enhance strategic direction and operational efficiency.

Looking ahead, RxSight anticipates continued revenue growth as it expands its sales territories and increases awareness of its products. The company believes that its existing cash and short-term investments, totaling $208.8 million, will be sufficient to fund operations for at least the next 12 months. RxSight plans to focus on increasing utilization of its LAL technology and may seek additional capital to support its growth initiatives, although it does not currently anticipate the need for further fundraising. The company remains committed to enhancing its product offerings and expanding its market presence, particularly in the premium intraocular lens segment.